The introduction of trastuzumab therapy markedly improved the poor prognosis associated
with HER2-amplified breast cancers. Despite this, the presence of primary and acquired …

Despite advances in surgery and chemotherapy and the integration of antivascular
endothelial growth factor therapy as well as poly (adenosine diphosphate–ribose) …

Simple Summary Epithelial ovarian cancer (EOC) is still the most lethal gynecological
cancer. In the recent years, the germline alterations in breast cancer 1 (gBRCA1) and breast …

Objective Metastatic HER2-positive breast cancer remains a significant clinical challenge
with a poor prognosis. The introduction of anti-HER2 therapies has significantly improved …

Background Platinum based chemotherapy is the treatment of choice for ovarian cancer
patients with a platinum treatment free interval of > 6 months. Niraparib is an oral poly …

Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in
the frontline therapy of advanced epithelial ovarian carcinoma during the last decade …

Simple Summary This is a collaborative approach between two multicentre structures, the
Spanish Group of Ovarian Cancer Research (GEICO) and the Spanish Biobank Network …

Background Platinum based chemotherapy is the treatment of choice for ovarian cancer
patients with a platinum treatment free interval of> 6 months. Niraparib is an oral poly (ADP …

Germline and tumor BRCA testing constitutes a valuable tool for clinical decision-making in
the management of epithelial ovarian cancer (EOC) patients. Tissue testing is able to identify …

Background Trastuzumab significantly improves overall survival (OS) when added to
cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers …